Biosimilar Therapeutic Peptides Market Report 2026

The biosimilar therapeutic peptides market size has grown rapidly in recent years. It will grow from $3.5 billion in 2025 to $3.9 billion in 2026 at a compound annual growth rate (CAGR) of 11.5%. The growth in the historic period can be attributed to limited availability of biosimilar peptides, reliance on innovative peptide therapies, growing prevalence of cancer and metabolic disorders, increasing awareness of peptide-based treatments, development of parenteral administration methods.

The biosimilar therapeutic peptides market size is expected to see rapid growth in the next few years. It will grow to $6.11 billion in 2030 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to launch of combination and long-acting peptides, expansion of generic peptide production, increasing adoption of transdermal delivery systems, rising investment in peptide research and development, growing healthcare expenditure on peptide therapeutics. Major trends in the forecast period include rising demand for biosimilar therapeutic peptides in cancer treatment, growth in peptide-based therapies for metabolic and cardiovascular disorders, increasing adoption of long-acting and combination peptides, expansion of parenteral and transdermal administration routes, focus on cost-effective generic peptides and accessibility in emerging markets.

The widespread occurrence of chronic diseases is anticipated to support the expansion of the biosimilar therapeutic peptide market. Chronic diseases are long-term health conditions that require continuous management and treatment, often persisting for many years or throughout a patient’s lifetime. The growing burden of chronic illnesses increases demand for affordable and effective therapies, positioning biosimilar therapeutic peptides as an appealing option due to their lower cost and ability to improve patient access while supporting healthcare system sustainability. In addition, regulatory backing and accumulating clinical evidence continue to reinforce market growth. For example, in April 2025, according to the Centers for Disease Control and Prevention (CDC), a US-based federal agency, around 194 million adults in the United States, representing 76.4% of the adult population, reported having at least one chronic condition in 2023. The prevalence was 59.5% among young adults, 78.4% among middle-aged adults, and 93% among older adults. Consequently, the rising prevalence of chronic diseases is expected to drive growth in the biosimilar therapeutic peptides market.

Leading companies in the biosimilar therapeutic peptide market are focusing on the development of research platforms aimed at optimizing peptide synthesis, improving manufacturing efficiency, and ensuring consistent product quality from early discovery through commercialization. Platforms such as the Biodrug Design Accelerator are designed to manage and streamline research processes for peptide drug discovery, which is increasingly viewed as a promising area in novel drug development. For instance, in May 2023, Fujitsu Limited launched the Biodrug Design Accelerator platform to accelerate research in peptide drug discovery. The platform is intended to support scientists in pharmaceutical companies by improving the speed and efficiency of peptide drug development through integrated design, make, test, and analyze (DMTA) cycles, enabling faster and more informed candidate selection as well as better collaboration among researchers involved in synthesis and testing.

In September 2024, Biocon Limited, an India-based biopharmaceutical company, entered into a partnership with Tabuk Pharmaceuticals to commercialize its glucagon-like peptide-1 (GLP-1) products across the Middle East. This collaboration is designed to increase the availability and adoption of Biocon’s GLP-1 therapies, improve treatment options for patients with metabolic disorders, and support growth and innovation in the Middle Eastern diabetes care market. Tabuk Pharmaceuticals is a Saudi Arabia-based pharmaceutical company specializing in the distribution and commercialization of innovative healthcare products.

Major companies operating in the biosimilar therapeutic peptides market are Pfizer Inc., Merck & Co. Inc., Novartis AG, Sanofi SA, Takeda Pharmaceuticals Co. Ltd., Eli Lilly and Company, Novo Nordisk A/S, Apotex Inc., Teva Pharmaceuticals Industries Ltd., Sandoz International GmbH, Lonza Inc., Stada Arzneimittel AG, Ipsen S.A, Biocon Biopharmaceuticals Pvt. Ltd., Dr. Reddy's Laboratories Ltd., Alvogen Pharma US Inc., Corden Pharma GmbH, Bachem Holding AG, PolyPeptide Laboratories Ltd.

North America was the largest region in the biosimilar therapeutics peptides market in 2025. Middle East is expected to be the fastest growing region in the biosimilar therapeutic peptides market report during the forecast period. The regions covered in the biosimilar therapeutic peptides market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biosimilar therapeutic peptides market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the biosimilar therapeutic peptides market by increasing costs of imported raw materials, peptide hormones, and delivery devices. Segments like innovative long-acting peptides and combination peptides are most affected, particularly in North America, Europe, and Asia-Pacific regions such as China and India. These tariffs have led to higher production costs and potential delays in drug availability. On the positive side, tariffs have promoted local manufacturing, encouraged innovation in cost-effective peptide therapies, and supported diversification of supply chains.

The biosimilar therapeutic peptides market research report is one of a series of new reports that provides biosimilar therapeutic peptides market statistics, including biosimilar therapeutic peptides industry global market size, regional shares, competitors with a biosimilar therapeutic peptides market share, detailed biosimilar therapeutic peptides market segments, market trends and opportunities, and any further data you may need to thrive in the biosimilar therapeutic peptides industry. This biosimilar therapeutic peptides market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biosimilar therapeutic peptides are peptide-based drugs that are administered as substitutes for, or supplements to, peptide hormones when the body’s natural levels begin to decline. These biosimilar therapeutic peptides are used in the treatment of cancer, metabolic conditions, pulmonary diseases, cardiovascular disorders, and other illnesses.

The main types of biosimilar therapeutic peptides include innovative and generic categories. Biosimilar medicines are often confused with generic drugs, as both are marketed as lower-cost alternatives to expensive branded medications. However, the key difference is that generics are exact copies of synthetic drugs, while biosimilars are derived from medicines that use biological organisms as active components. The various routes of administration include parenteral, transdermal, and others, and these peptides are used across cancer, cardiovascular disorders, central nervous system conditions, metabolic disorders, infections, hematological disorders, gastrointestinal disorders, dermatology, and respiratory disorders.

The biosimilar therapeutic peptides market consists of sales of pegfilgrastim, bevacizumab, and adalimumab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.